《生命科学》 2022, 34(3): 254-260

嵌合抗原受体T细胞治疗原发性肝癌研究进展

刘圣艳¹ , 朱丽晨¹ , 赵欣悦¹ , 施　维¹ , 杨晓梅^1,* , 卢小玲^2,*

¹广西医科大学基础医学院，广西纳米抗体研究重点实验室，广西纳米抗体国际联合研究中心，南宁 530021 ²广西医科大学附属口腔医学院，广西纳米抗体研究重点实验室，广西纳米抗体国际联合研究中心，南宁 530021

摘　要：

近30 年来，CAR 技术已经从第一代发展到第五代。CAR-T 细胞疗法治疗原发性肝癌取得了很大进展，但仍存在挑战。该文将对CAR-T 细胞治疗原发性肝癌所选择的靶点进行总结，对CAR-T 细胞疗法治疗原发性肝癌的临床前研究和临床研究进行回顾，另外还将对CAR-T 细胞疗法治疗原发性肝癌面临的挑战及解决措施进行综述。

通讯作者：杨晓梅 , Email:260718428@qq.com 卢小玲 , Email:luxiaoling@gxmu.edu.cn

Advances in the treatment of primary hepatic carcinoma with chimeric antigen receptor T cells

LIU Sheng-Yan¹ , ZHU Li-Chen¹ , ZHAO Xin-Yue¹ , SHI Wei¹ , YANG Xiao-Mei^1,* , LU Xiao-Ling^2,*

¹International Nanobody Research Center of Guangxi, Key Nanobody Research Laboratory of Guangxi, Basic Medical College of Guangxi Medical University, Nanning 530021, China ²International Nanobody Research Center of Guangxi, Key Nanobody Research Laboratory of Guangxi, Department of Stomatology, Stomatology College of Guangxi Medical University, Nanning 530021, China

Abstract:

For nearly 30 years, the technology of CARs have been developed from the first generation to the fifth generation. CAR-T cell therapy in the treatment of primary hepatic carcinoma has made great progress, but it is still a challenge. Herein, we will summarize the selected targets for CAR-T cells in the treatment of primary liver cancer, and review both the preclinical trials and clinical trials of CAR-T cell therapy for primary liver cancer. Moreover, the challenges and solutions of CAR-T cell therapy for primary liver cancer will also be reviewed in this article.

Communication Author：YANG Xiao-Mei , Email:260718428@qq.com LU Xiao-Ling , Email:luxiaoling@gxmu.edu.cn